Skip to main content

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Integra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 2, 2026, Integra pre-announced disappointing operational performance and cut its full-year 2026 revenue guidance range by $30.5 million at the midpoint. The Company revealed that severe flooding at its Cincinnati facility in July 2026 had caused widespread operational disruptions, impacting third-quarter revenues by roughly $7 million and creating an anticipated $15 million to $20 million headwind for the fourth quarter.

On this news, Integra’s stock price fell $3.41 per share, or 21.2%, to close at $12.68 per share on October 2, 2026.

Then, on October 21, 2026, Integra released its finalized third-quarter 2026 financial results, confirming a revenue miss of $411.2 million against internal and analyst expectations. The Company admitted that the Cincinnati facility disruption was worse than originally anticipated and disclosed that execution pressure and competitive headwind constraints had driven an organic revenue contraction of 2.2% within its critical Tissue Reconstruction segment.

On this news, Integra’s stock price fell $1.17 per share, or 8.76%, to close at $12.16 per share on October 21, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980


Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.10
+4.01 (1.61%)
AAPL  347.10
+3.19 (0.93%)
AMD  560.26
+28.98 (5.45%)
BAC  50.68
+0.16 (0.32%)
GOOG  316.83
+2.64 (0.84%)
META  620.19
-10.37 (-1.64%)
MSFT  531.33
-1.27 (-0.24%)
NVDA  217.94
+1.94 (0.90%)
ORCL  130.53
+4.47 (3.55%)
TSLA  407.46
+15.84 (4.04%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.